scholarly journals One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure

Author(s):  
Lisa Wahlgren ◽  
Anna-Karin Kroksmark ◽  
Mar Tulinius ◽  
Kalliopi Sofou

AbstractDuchenne muscular dystrophy (DMD) is a severe neuromuscular disorder with increasing life expectancy from late teens to over 30 years of age. The aim of this nationwide study was to explore the prevalence, life expectancy and leading causes of death in patients with DMD in Sweden. Patients with DMD were identified through the National Quality Registry for Neuromuscular Diseases in Sweden, the Swedish Registry of Respiratory Failure, pathology laboratories, neurology and respiratory clinics, and the national network for neuromuscular diseases. Age and cause of death were retrieved from the Cause of Death Registry and cross-checked with medical records. 373 DMD patients born 1970–2019 were identified, of whom 129 patients deceased during the study period. Point prevalence of adult patients with DMD on December 31st 2019 was 3.2 per 100,000 adult males. Birth prevalence was 19.2 per 100,000 male births. Median survival was 29.9 years, the leading cause of death being cardiopulmonary in 79.9% of patients. Non-cardiopulmonary causes of death (20.1% of patients) mainly pertained to injury-related pulmonary embolism (1.3 per 1000 person-years), gastrointestinal complications (1.0 per 1000 person-years), stroke (0.6 per 1000 person-years) and unnatural deaths (1.6 per 1000 person-years). Death from non-cardiopulmonary causes occurred at younger ages (mean 21.0 years, SD 8.2; p = 0.004). Age at loss of independent ambulation did not have significant impact on overall survival (p = 0.26). We found that non-cardiopulmonary causes contribute to higher mortality among younger patients with DMD. We present novel epidemiological data on the increasing population of adult patients with DMD.

2020 ◽  
Author(s):  
Justin S. Dhindsa ◽  
Angela L. McCall ◽  
Laura M. Strickland ◽  
Anna F. Fusco ◽  
Amanda F. Kahn ◽  
...  

AbstractSkeletal muscle weakness due to loss of dystrophin is a well-documented pathological hallmark of Duchenne muscular dystrophy (DMD). In contrast, the neuropathology of this disease remains understudied. Here, we characterize an axonopathy in the phrenic and hypoglossal (XII) nerves of mdx mice. We observe nerve dysfunction that we propose contributes to respiratory failure, the most common cause of death in DMD.


Author(s):  
Andrea Vianello ◽  
Giovanna Arcaro ◽  
Gabriella Guarnieri ◽  
Andi Sukthi ◽  
Beatrice Molena ◽  
...  

2018 ◽  
Vol 22 (5) ◽  
pp. 786-790 ◽  
Author(s):  
Yuka Yamada ◽  
Michiyuki Kawakami ◽  
Ayako Wada ◽  
Shogo Fukui ◽  
Koshiro Haruyama ◽  
...  

2021 ◽  
Vol 2 (3) ◽  
pp. 159-166
Author(s):  
Alexey L. Kurenkov ◽  
Lyudmila M. Kuzenkova ◽  
Lale A. Pak ◽  
Bella I. Bursagova ◽  
Tatyana V. Podkletnova ◽  
...  

Duchenne muscular dystrophy (DMD) is a disease with an X-linked recessive type of inheritance, belonging to a group of disorders with primary muscle damage, caused by pathogenic variants in the DMD gene and associated with dysfunction of the dystrophin protein. Since DMD is manifested by the gradual development of progressive, mainly proximal muscle weakness, the differential diagnosis is primarily carried out in the group of diseases with muscle damage - myopathies. Among these diseases, the leading candidates for differential diagnosis are hereditary myopathies (limb-girdle muscular dystrophies, facioscapulohumeral dystrophy, congenital muscular dystrophies, glycogenoses - the most common juvenile form of glycogenosis type II (Pompe disease)) and, much less often, congenital myopathies and other conditions of neuromuscular diseases). When conducting a differential diagnosis in a child with suspected DMD, the age of the onset of the disease, early initial clinical manifestations and the development of symptoms as they grow, genealogical analysis, laboratory tests (the level of creatine kinase, aspartate aminotransferase, alanine aminotransferase in blood serum), instrumental (electromyography, magnetic resonance imaging of the brain and muscles) and molecular genetics (polymerase chain reaction, multiplex ligation-dependent probe amplification, next-generation sequencing, Sanger sequencing, etc.) of studies, and in some cases, muscle biopsy data. Knowledge of the nuances of the differential diagnosis allows establishing a genetic diagnosis of DMD as early as possible, which is extremely important for the formation of the prognosis of the disease and the implementation of all available treatment methods, including pathogenetic therapy, and is also necessary for medical and genetic counselling of families with DMD patients.


2019 ◽  
Vol 38 (4) ◽  
pp. S116-S117
Author(s):  
C.A. Wittlieb-Weber ◽  
K.K. Knecht ◽  
C.R. Villa ◽  
C. Cunningham ◽  
M.J. Bock ◽  
...  

2020 ◽  
Vol 35 (7) ◽  
pp. 643-653 ◽  
Author(s):  
Erik Landfeldt ◽  
Rachel Thompson ◽  
Thomas Sejersen ◽  
Hugh J. McMillan ◽  
Janbernd Kirschner ◽  
...  

2020 ◽  
Vol 41 (4) ◽  
pp. 764-771
Author(s):  
Carol A. Wittlieb-Weber ◽  
Kenneth R. Knecht ◽  
Chet R. Villa ◽  
Chentel Cunningham ◽  
Jennifer Conway ◽  
...  

Respiration ◽  
2014 ◽  
Vol 87 (6) ◽  
pp. 499-503 ◽  
Author(s):  
Christian M. Lo Cascio ◽  
Tsogyal D. Latshang ◽  
Malcolm Kohler ◽  
Thomas Fehr ◽  
Konrad E. Bloch

Sign in / Sign up

Export Citation Format

Share Document